Imlifidase as pretreatment in gene therapy for patients with Crigler–Najjar syndrome who are immune to AAV On October 10, 2025, Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced that…..
